Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.21  +0.02 (+1.68%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PYXS. PYXS was compared to 558 industry peers in the Biotechnology industry. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PYXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PYXS has reported negative net income.
PYXS had a negative operating cash flow in the past year.
PYXS had negative earnings in each of the past 5 years.
In the past 5 years PYXS always reported negative operating cash flow.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PYXS has a worse Return On Assets (-70.09%) than 63.62% of its industry peers.
PYXS has a Return On Equity (-92.37%) which is in line with its industry peers.
Industry RankSector Rank
ROA -70.09%
ROE -92.37%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PYXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
PYXS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PYXS has been increased compared to 5 years ago.
PYXS has a worse debt/assets ratio than last year.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.84, we must say that PYXS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.84, PYXS perfoms like the industry average, outperforming 45.52% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that PYXS is not too dependend on debt financing.
PYXS's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. PYXS outperforms 48.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.84
ROIC/WACCN/A
WACC9.68%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.75 indicates that PYXS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.75, PYXS is in the better half of the industry, outperforming 69.53% of the companies in the same industry.
PYXS has a Quick Ratio of 7.75. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
PYXS has a Quick ratio of 7.75. This is in the better half of the industry: PYXS outperforms 69.89% of its industry peers.
Industry RankSector Rank
Current Ratio 7.75
Quick Ratio 7.75
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

PYXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.82%, which is quite good.
PYXS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)8.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-483.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -0.82% on average over the next years.
The Revenue is expected to grow by 39.00% on average over the next years. This is a very strong growth
EPS Next Y-47.81%
EPS Next 2Y-13.27%
EPS Next 3Y-9.81%
EPS Next 5Y-0.82%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-23.57%
Revenue Next 5Y39%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PYXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

PYXS's earnings are expected to decrease with -9.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.27%
EPS Next 3Y-9.81%

More info and screens

0

5. Dividend

5.1 Amount

PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (7/15/2025, 2:15:57 PM)

1.21

+0.02 (+1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners38.31%
Inst Owner Change0%
Ins Owners6.68%
Ins Owner Change0%
Market Cap74.96M
Analysts84.62
Price Target6.32 (422.31%)
Short Float %10.68%
Short Ratio9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.51%
Min EPS beat(2)-16.71%
Max EPS beat(2)25.73%
EPS beat(4)2
Avg EPS beat(4)2.96%
Min EPS beat(4)-16.71%
Max EPS beat(4)25.73%
EPS beat(8)5
Avg EPS beat(8)18.62%
EPS beat(12)6
Avg EPS beat(12)14.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.09%
EPS NQ rev (1m)-0.48%
EPS NQ rev (3m)-22.11%
EPS NY rev (1m)-20.23%
EPS NY rev (3m)-21.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS0
BVpS1.66
TBVpS1.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -70.09%
ROE -92.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.75
Quick Ratio 7.75
Altman-Z -3.84
F-Score1
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-483.33%
EPS Next Y-47.81%
EPS Next 2Y-13.27%
EPS Next 3Y-9.81%
EPS Next 5Y-0.82%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-23.57%
Revenue Next 5Y39%
EBIT growth 1Y-28.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.77%
OCF growth 3YN/A
OCF growth 5YN/A